Your browser doesn't support javascript.
loading
A multi-center, randomized, double-blinded, parallel, placebo-controlled study to assess the efficacy and safety of Shenqisuxin granule in complex coronary artery disease after PCI: Study protocol.
Wu, Xiaoping; Yan, Mingyu; Pang, Xingxue; Wu, Hui; Hu, Zhigeng; Xiao, Rui; Pan, Jianlue; Li, Ying; Shi, Shengnan; Deng, Yanping; Li, Jiaxi; Wang, Peili; Chen, Keji.
Afiliación
  • Wu X; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Yan M; Graduate School of China Academy of Chinese Medical Sciences, Beijing, China.
  • Pang X; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Wu H; Graduate School of Beijing University of Chinese Medicine, Beijing, China.
  • Hu Z; Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Xiao R; Department of Cardiovascular, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Pan J; Cardiovascular Diseases Center, The Affiliated Hospital of Shanxi University of Chinese Medicine, Taiyuan, China.
  • Li Y; Cardiovascular Diseases Center, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
  • Shi S; Department of Cardiovascular, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Deng Y; Cardiovascular Diseases Center, The Affiliated Hospital of Shanxi University of Chinese Medicine, Taiyuan, China.
  • Li J; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
  • Wang P; Graduate School of China Academy of Chinese Medical Sciences, Beijing, China.
  • Chen K; National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Cardiovasc Med ; 9: 1000379, 2022.
Article en En | MEDLINE | ID: mdl-36262203
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Cardiovasc Med Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Cardiovasc Med Año: 2022 Tipo del documento: Article País de afiliación: China